Showing 5131-5140 of 5957 results for "".
- Apellis Completes Enrollment in Two Phase 3 Studies of Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-completes-enrollment-in-two-phase-3-studies-of-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2477978/Apellis Pharmaceuticals announced that it completed enrollment in the phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan (APL-2), a targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA causes blind
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients 3 Years After Lumevoq Treatmenthttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-among-lhon-patients-3-years-after-lumevoq-treatment/2477972/GenSight Biologics reported that Leber Hereditary Optical Neuropathy (LHON) subjects treated with Lumevoq experienced sustained efficacy and safety 3 years after a single injection with the gene therapy. These findings come from CLIN06, the long-term follow-up study to which participants in the R
- Patrick F. Williams Appointed Chief Financial Officer of Staar Surgicalhttps://modernod.com/news/patrick-f-williams-appointed-chief-financial-officer-of-staar-surgical/2477969/Staar Surgical announced that Patrick F. Williams has joined the company as Chief Financial Officer, effective today. Mr. Williams is reporting to Caren Mason, President and Chief Executive Officer. His appointment is part of a planned transition following Deborah Andrews’ previously announced re
- Retinopathy Risk Increased in T2DM After Cataract Surgeryhttps://modernod.com/news/retinopathy-risk-increased-in-t2dm-after-cataract-surgery/2477965/People with type 2 diabetes are more likely to develop diabetic retinopathy (DR) after cataract surgery, according a new population-based study, according to a Reuters report. Over six years of follow-up, the adjusted risk of retino
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- HHS: COVID-19 Testing Reaching Capacity at Some Labs as States Grapple With Spikeshttps://modernod.com/news/hhs-covid-19-testing-reaching-capacity-at-some-labs-as-states-grapple-with-spikes/2477964/Some laboratories across the country are reaching or near capacity on COVID-19 testing as cases start to rise to record levels in some states, according to a FierceHealthcare
- Global COVID-19 Prevention Trial of Hydroxychloroquine to Resumehttps://modernod.com/news/global-covid-19-prevention-trial-of-hydroxychloroquine-to-resume/2477960/A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators, according to a Reuters report. The Medic
- Oculight Launches US Subsidiary OCU L&Chttps://modernod.com/news/oculight-launches-us-subsidiary-ocu-lc/2477956/Oculight announced the launch of OCU L&C, a fully-owned U.S. subsidiary. OCU L&C will focus on the commercialization of its products in the U.S. Oculight is an ophthalmic medical device developer based in Korea founded in 2017 by Dr.
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s